Treatment of advanced primary lung cancer associated with malignant pleural effusion by the combination of immunotherapy and chemotherapy.
Twelve patients with advanced primary lung cancers associated with malignant pleural effusion were treated with intrathoracic instillation of recombinant interleukin-2 with or without in-vitro-sensitized cells. Two cases achieved complete response, and 7 partial response. The adverse effects seen in the protocol were marginal, and the protocol was well-tolerated and feasible. Furthermore, 4 cases were treated with the combination of systemic chemotherapy and adoptive immunotherapy. Of these, 3 cases responded well to the therapy and have shown a complete response for more than 20 months, indicating that adoptive immunotherapy together with chemotherapy might be a beneficial treatment for advanced lung cancer patients.
Miyao
H
H
Department of Medicine (II), Niigata University Medical School, Japan.
Chou
T
T
Ito
K
K
Moriyama
H
H
Mitsuma
S
S
Wakabayashi
M
M
Yoshizawa
H
H
Arakawa
M
M
D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy*; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017252:CD3 Complex / Q000276:immunology; D018288:Carcinoma, Small Cell / Q000473:pathology / Q000628:therapy*; D002478:Cells, Cultured; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000627:therapeutic use*; D007937:Leukapheresis; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*; D008214:Lymphocytes / Q000276:immunology / Q000528:radiation effects; D008297:Male; D008875:Middle Aged; D010996:Pleural Effusion / Q000276:immunology / Q000473:pathology; D011994:Recombinant Proteins / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D017252:CD3 Complex; D007376:Interleukin-2; D011994:Recombinant Proteins